Medtelligence: Linking Science to Clinical Practice - Medtelligence

Medtelligence Hero

Linking Science
to Clinical Practice

Innovative, high-quality medical education for clinicians in cardiology and other specialties.

Featured

Transforming Care in Pediatric Patients With C3 Glomerulopathy: Targeting C3 at the Source
Transforming Care in Pediatric Patients With C3 Glomerulopathy: Targeting C3 at the Source
CME/CE
Transforming Care in Pediatric Patients With C3 Glomerulopathy: Targeting C3 at the Source
Richard Lafayette, MD, FACP; Ankana Daga, MD
0.25 credits
- Richard Lafayette, MD, FACP
- Ankana Daga, MD
0.25 credits
Stuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider!
Stuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider!
CME/CE
Stuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider!
Antoine Lanot, MD, PhD; Gil Yosipovitch, MD
0.25 credits
- Antoine Lanot, MD, PhD
- Gil Yosipovitch, MD
0.25 credits
MinuteCE®
Modern Obstructive HCM Care: From Unmet Needs to Individualized Myosin Inhibitor Therapy
Ahmad Masri, MD, MS; Michael Nassif, MD, MSc
1.00 credit 8 episodes
- Ahmad Masri, MD, MS
- Michael Nassif, MD, MSc
- Anjali Owens, MD
1.00 credit 8 episodes
Real-World IgAN: A Case-Based Approach to Maximizing Kidney Preservation
Real-World IgAN: A Case-Based Approach to Maximizing Kidney Preservation
CME/CE
Real-World IgAN: A Case-Based Approach to Maximizing Kidney Preservation
An De Vriese, MD, PhD; Muh Geot Wong, MBBS, PhD
0.25 credits
- An De Vriese, MD, PhD
- Muh Geot Wong, MBBS, PhD
0.25 credits

Popular

NEW EPISODE
Modern Obstructive HCM Care: From Unmet Needs to Individualized Myosin Inhibitor Therapy
Modern Obstructive HCM Care: From Unmet Needs to Individualized Myosin Inhibitor Therapy
MinuteCE®
Modern Obstructive HCM Care: From Unmet Needs to Individualized Myosin Inhibitor Therapy
Anjali Owens, MD; Ahmad Masri, MD, MS
1.00 program credit
- Anjali Owens, MD
- Ahmad Masri, MD, MS
1.00 program credit
Safety in oHCM Therapy: How and When to Transition Treatment?
Safety in oHCM Therapy: How and When to Transition Treatment?
MinuteCE®
Safety in oHCM Therapy: How and When to Transition Treatment?
Anjali Owens, MD
1.00 program credit
- Anjali Owens, MD
1.00 program credit
Hypertrophic Cardiomyopathy: Overcoming Practical Barriers to Treatment in the Era of Myosin Inhibitors
Hypertrophic Cardiomyopathy: Overcoming Practical Barriers to Treatment in the Era of Myosin Inhibitors
Cardiology
Hypertrophic Cardiomyopathy: Overcoming Practical Barriers to Treatment in the Era of Myosin Inhibitors
Florian Rader, MD
- Florian Rader, MD
Hypertrophic Cardiomyopathy: Moving From Monitoring to Action in the Era of Myosin Inhibitors
Hypertrophic Cardiomyopathy: Moving From Monitoring to Action in the Era of Myosin Inhibitors
Cardiology
Hypertrophic Cardiomyopathy: Moving From Monitoring to Action in the Era of Myosin Inhibitors
Joseph Rossano, MD
- Joseph Rossano, MD
Molecular Precision: How Myosin Inhibitors Redefine Control
Molecular Precision: How Myosin Inhibitors Redefine Control
MinuteCE®
Molecular Precision: How Myosin Inhibitors Redefine Control
Ahmad Masri, MD, MS; Anjali Owens, MD
1.00 program credit
- Ahmad Masri, MD, MS
- Anjali Owens, MD
1.00 program credit
Redefining oHCM Care: Efficacy and Safety of Myosin Inhibitors
Redefining oHCM Care: Efficacy and Safety of Myosin Inhibitors
MinuteCE®
Redefining oHCM Care: Efficacy and Safety of Myosin Inhibitors
Michael Nassif, MD, MSc; Anjali Owens, MD
1.00 program credit
- Michael Nassif, MD, MSc
- Anjali Owens, MD
1.00 program credit
From Evidence to Action: Integrating Emerging Myosin Inhibitors Into oHCM Treatment Plans
From Evidence to Action: Integrating Emerging Myosin Inhibitors Into oHCM Treatment Plans
MinuteCE®
From Evidence to Action: Integrating Emerging Myosin Inhibitors Into oHCM Treatment Plans
Michael Nassif, MD, MSc; Anjali Owens, MD
1.00 program credit
- Michael Nassif, MD, MSc
- Anjali Owens, MD
1.00 program credit
From Beta-Blockers to Myosin Inhibitors: Initial Decision-Making in Obstructive HCM
From Beta-Blockers to Myosin Inhibitors: Initial Decision-Making in Obstructive HCM
MinuteCE®
From Beta-Blockers to Myosin Inhibitors: Initial Decision-Making in Obstructive HCM
Ahmad Masri, MD, MS; Anjali Owens, MD
1.00 program credit
- Ahmad Masri, MD, MS
- Anjali Owens, MD
1.00 program credit